Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03664921 · ClinicalTrials.gov registry record · Phase 2
Omnitram Safety and Efficacy in the Treatment of Diabetic Neuropathy
A Phase 2 study, sponsored by Syntrix Biosystems.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT03664921 is a Phase 2 study that has completed, run by Syntrix Biosystems. The registered enrollment target is 55 participants.
The verdict
NCT03664921, a Phase 2 study, has completed, sponsored by Syntrix Biosystems.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
This study evaluates the analgesic effect of Omnitram for the treatment of painful diabetic neuropathy. Each subject with diabetic neuropathy will be treated for four weeks with Omnitram and for four weeks with placebo. The order of the Omnitram and placebo treatment will be random.
Interventions
- DRUG Placebo Oral Tablet
- DRUG Omnitram Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2018-11-15 |
| Est. Completion | 2020-08-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03664921
The ClinicalTrials.gov registry entry for NCT03664921 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Syntrix Biosystems, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT03664921 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03664921 about?
NCT03664921 is a clinical study titled "Omnitram Safety and Efficacy in the Treatment of Diabetic Neuropathy". This study evaluates the analgesic effect of Omnitram for the treatment of painful diabetic neuropathy. Each subject with diabetic neuropathy will be treated for four weeks with Omnitram and for four weeks with placebo. The order of the Omnitram and placebo treatment will be random.
What is the current status of trial NCT03664921?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2018-11-15. Estimated completion is 2020-08-17.
What interventions are being tested in trial NCT03664921?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Omnitram Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT03664921?
This trial is sponsored by Syntrix Biosystems, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.